Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients
dc.contributor.author | Luan, Fu L | en_US |
dc.contributor.author | Samaniego, Millie D. | en_US |
dc.contributor.author | Kommareddi, Mallika | en_US |
dc.contributor.author | Park, J. M. | en_US |
dc.contributor.author | Ojo, Akinlolu O. | en_US |
dc.date.accessioned | 2011-01-31T17:52:04Z | |
dc.date.available | 2012-02-21T18:47:01Z | en_US |
dc.date.issued | 2010-12 | en_US |
dc.identifier.citation | Luan, F.L.; Samaniego, M.; Kommareddi, M.; Park, J.M.; Ojo, A.O.; (2010). "Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients." Transplant Infectious Disease 12(6): 473-479. <http://hdl.handle.net/2027.42/79309> | en_US |
dc.identifier.issn | 1398-2273 | en_US |
dc.identifier.issn | 1399-3062 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/79309 | |
dc.description.abstract | F.L. Luan, M. Samaniego, M. Kommareddi, J.M. Park, A.O. Ojo. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients. Transpl Infect Dis 2010: 12: 473–479. All rights reservedLate occurrence of cytomegalovirus (CMV) infection remains a concern in CMV-seronegative kidney and/or pancreas transplant recipients of CMV-seropositive organs (donor positive/recipient negative, D+/R−) despite the use of prophylaxis. We investigated the impact of various antibody induction regimens on CMV infection in this group of patients.A total of 254 consecutive D+/R− kidney and/or pancreas transplant patients were studied. The induction agents rabbit anti-thymocyte globulin (rATG) or basiliximab were used according to the center practice. All patients received prophylaxis with valganciclovir (VGCV) for either 3 or 6 months. The occurrence of CMV infection was confirmed by positive DNA viremia. Multivariate Cox regression analyses were performed to determine risk factors for CMV infection.The cumulative incidence of CMV infection was 58, 112, and 59 cases per 1000 patient-years for patients who received no antibody induction, induction with rATG, or basiliximab induction, respectively ( P =0.02). The use of rATG but not basiliximab was associated with an increased risk for CMV infection (adjusted hazard ratio [AHR] 2.13, 95% confidence interval [CI] 1.24–3.54, P =0.006). Acute rejection and its treatment with rATG were not associated with an increased risk for CMV infection when an additional course of VGCV was given following the treatment. Longer duration of prophylaxis was associated with a reduced risk for CMV infection (AHR 0.54, 95% CI 0.33–0.87, P =0.011).Induction with rATG is associated with increased risk of CMV infection. Longer duration of prophylaxis is beneficial. | en_US |
dc.format.extent | 158385 bytes | |
dc.format.extent | 3106 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Inc | en_US |
dc.subject.other | Cytomegalovirus | en_US |
dc.subject.other | Kidney Transplant | en_US |
dc.subject.other | Pancreas Transplant | en_US |
dc.subject.other | Donor/Recipient Mismatch | en_US |
dc.subject.other | Rabbit Anti-thymocyte Globulin | en_US |
dc.subject.other | Basiliximab | en_US |
dc.subject.other | Acute Rejection | en_US |
dc.title | Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationum | Department of Pharmacy Service, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA | en_US |
dc.identifier.pmid | 20576019 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/79309/1/j.1399-3062.2010.00532.x.pdf | |
dc.identifier.doi | 10.1111/j.1399-3062.2010.00532.x | en_US |
dc.identifier.source | Transplant Infectious Disease | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.